Cited by 144Pneumonia and Respiratory InfectionsBacterial Infections and VaccinesImmunodeficiency and Autoimmune Disorders

Immunological responses to pneumococcal vaccine in frail older people

Ridda, I., MacIntyre, C.R., Lindley, R., Gao, Z., Sullivan, J.S., Yuan, F.F., McIntyre, P.B.·2009·Vaccine

Abstract

Unlabelled Advanced age has been associated with a wide range of defects in both the innate and adaptive immune systems including diminished specific antibody responses that increase the risk of invasive pneumococcal disease (IPD) and limit the effectiveness of vaccines. However, the elderly are a heterogeneous group and measures of overall frailty may be a better indicator of disease susceptibility (or vaccine response) than chronological age alone.Aim To evaluate the immunogenicity of the 7-valent conjugated pneumococcal vaccine (PCV7) versus 23-valent polysaccharide vaccine (23vPPV) and compare the immune response to four serotypes (4, 6B, 18C and 19F), with respect to age or frailty in an elderly population of previously unvaccinated hospitalized patients.Method 241 patients aged 60 years and over, recruited between 16 May 2005 and 20 February 2006, were randomised to 23PPV or PCV7 vaccine. We measured Frailty Index (FI), Barthel index and the MiniMental State. Serotype-specific IgG was measured by ELISA at base line and 6 months after vaccination. Antibody responses were defined by the ratio of post-vaccination to pre-vaccination IgG antibody concentration (poor < 2-fold increase, acceptable > or = 2.0 to 3.99-fold and strong > or = 4.0-fold increase).Results Pre-immunization IgG was generally low and did not differ significantly by age or frailty. Post-immunization, IgG increased to all four serotypes; acceptable or strong response ranged between 29% for (6B) and 57% for (18C). There was no significant difference between the two vaccine types (23PPV versus PCV7). At 6 months post-vaccination, the highest geometric mean IgG concentrations (GMCs) were seen for serotype 19F and the lowest for serotype 4. Although there was some variation by serotype, responses after vaccination were lowest in the most frail or aged subjects.Conclusions Pneumococcal vaccines are perceived to offer low protection in the frail elderly, but our study showed that the proportion of this vulnerable population with acceptable responses is encouraging. Frailty, as measured by the Frailty Index, appears to be a better predictor of immune response to pneumococcal vaccines than age alone.

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2008.11.098

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Frailty is linked to weaker antibody responses to influenza and pneumococcal vaccines, which may explain why vaccination benefits older people only modestly.

    “Furthermore, frailty is associated with an impaired antibody response to influenza (63) and pneumococcal vaccine (64), which helps explain the observation that vaccination in older people is associated with only relatively modest clinical effectiveness (65).”

    From Frailty in elderly people (2013) · cites this paper as [64]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ridda, I., MacIntyre, C. R., Lindley, R., Gao, Z., Sullivan, J. S., Yuan, F. F., & McIntyre, P. B.
Affiliations
  • The University of Sydney (AU)
  • UNSW Sydney (AU)
  • National Centre for Immunisation Research & Surveillance (AU)
Corresponding author
Ridda, I.
Venue
Vaccine
Publisher
Elsevier BV
Published
2009-03
Volume
27
Issue
10
Pages
1628-1636
ISSN
0264-410X (ISSN-L)
OpenAlex
W1997721806
Cited by
144
References
38
Citations by year
2026: 3 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 8 · 2021: 9 · 2020: 5 · 2019: 8 · 2018: 5 · 2017: 11 · 2016: 8 · 2015: 6 · 2014: 7 · 2013: 13 · 2012: 18
FWCI
7.92
Type
journal article
Language
en
Open access
closed
Locations
  • Vaccine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
  • Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Keywords
pneumococcal vaccine, immunogenicity, frailty, older adults, 7-valent conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine, serotype-specific IgG, frailty index, serotype 19F, serotype 4, serotype 6B, serotype 18C, hospitalized older adults, vaccine response
MeSH terms
Heptavalent Pneumococcal Conjugate Vaccine, Aged, Aged, 80 and over, Antibodies, Bacterial, Female, Humans, Immunoglobulin G, Male, Middle Aged, Pneumococcal Infections, Streptococcus pneumoniae, Frail Elderly, Pneumococcal Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review